Rezolute, Inc. (NASDAQ:RZLT) Director Acquires $19,733.36 in Stock

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis purchased 6,758 shares of the company’s stock in a transaction on Monday, March 31st. The shares were bought at an average cost of $2.92 per share, with a total value of $19,733.36. Following the transaction, the director now directly owns 84,025 shares of the company’s stock, valued at $245,353. This represents a 8.75 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Wladimir Hogenhuis also recently made the following trade(s):

• On Tuesday, February 18th, Wladimir Hogenhuis acquired 10,000 shares of Rezolute stock. The shares were bought at an average cost of $4.70 per share, for a total transaction of $47,000.00.

Rezolute Price Performance

NASDAQ:RZLT traded up $0.02 during trading hours on Tuesday, reaching $2.92. 863,155 shares of the company were exchanged, compared to its average volume of 487,683. The firm has a market cap of $176.76 million, a price-to-earnings ratio of -2.39 and a beta of 0.95. The stock has a 50 day simple moving average of $4.22 and a 200 day simple moving average of $4.73. Rezolute, Inc. has a 52-week low of $2.22 and a 52-week high of $6.19.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. On average, analysts predict that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Rezolute

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in Rezolute by 39.0% in the third quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock valued at $2,385,000 after buying an additional 137,905 shares during the period. MML Investors Services LLC purchased a new position in shares of Rezolute in the 3rd quarter valued at $57,000. JPMorgan Chase & Co. acquired a new position in shares of Rezolute during the 3rd quarter valued at $42,000. State Street Corp boosted its position in Rezolute by 11.6% during the 3rd quarter. State Street Corp now owns 125,472 shares of the company’s stock worth $609,000 after purchasing an additional 13,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Rezolute in the 3rd quarter valued at $239,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RZLT has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Thursday, February 13th. JMP Securities upped their price objective on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a research note on Thursday, February 13th. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a research note on Monday, February 10th. Finally, Craig Hallum raised Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Rezolute currently has an average rating of “Buy” and an average target price of $24.38.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.